17.3 Central Fill, 503A, and 503B Outsourcing
Key Takeaways
- Central fill is not a transfer: the originating (retail) pharmacy sends prescription information to a central-fill pharmacy that prepares the product and returns it to the originating pharmacy for dispensing; patient counseling remains the originating pharmacy’s duty.
- For controlled substances, 21 CFR 1306.14(b) and 1306.24(b) require the dispensed label to show the retail (originating) pharmacy’s name and address plus a unique identifier — the central fill pharmacy’s DEA number — showing it was filled centrally; 21 CFR 1306.15 and 1306.27 require “CENTRAL FILL” documentation, dual DEA registration, and delivery-tracking records.
- FDCA § 503A is patient-specific (or limited anticipatory) USP 795/797 compounding in a state-licensed pharmacy; it cannot regularly copy a commercially available drug unless a documented significant patient-specific difference or a shortage/off-market situation applies, and FDA does not treat 503A as office-use manufacturing.
- FDCA § 503B outsourcing facilities register with FDA, follow cGMP, may compound with or without patient-specific prescriptions for office or hospital stock, and cannot claim 503A exemptions for drugs made at that same registered facility.
- Connecticut: non-patient-specific sterile supply requires a CGS § 21a-70 manufacturer/wholesaler certificate plus any required federal (503B) registration (CGS § 20-633b(d)(2)); a nonresident pharmacy that ships into Connecticut needs CGS § 20-627 registration and, if sterile, the § 20-633b addendum and inspection reports.
Originating pharmacy versus central fill — NABP 4.6
Quick Answer: Central fill is a fulfillment arrangement, not a prescription transfer. The originating (retail) pharmacy receives the prescription, remains responsible for DUR and counseling, and is the name on the patient’s label. The central-fill pharmacy prepares the product and returns it to the originating pharmacy for dispensing to the patient. For controlled substances, write “CENTRAL FILL” on the original, both pharmacies keep DEA-required records, and the label shows the retail pharmacy name and address plus the central fill DEA number as the unique identifier (21 CFR 1306.14(b), 1306.24(b), 1306.15, 1306.27). 503A is patient-specific USP compounding. 503B is FDA-registered cGMP outsourcing. Do not mix them at the same facility.
NABP Competency 4.6 is central fill. Competency 4.5 is compounding. This section is where the exam ties both to FDCA §§ 503A and 503B and to Connecticut’s nonresident and § 21a-70 gates.
DEA defines a central fill pharmacy as a pharmacy authorized by the state to fill prescriptions on behalf of retail pharmacies with which it has a contractual agreement or a common owner, for delivery to the retail pharmacy (21 CFR 1300.01). Connecticut does not publish a separate “central-fill permit” class. Each site still needs the § 20-594 pharmacy license it already holds, or a § 20-627 nonresident registration if it is outside Connecticut and ships in, plus DEA registration if controlled substances move.
Who appears on the label, and who counsels
The patient walked into — or called — the originating pharmacy. That is the pharmacy relationship OBRA ’90 and Connecticut counseling duties attach to (Chapter 11). Central fill does not move counseling to a warehouse pharmacist the patient will never meet.
For Schedule II, 21 CFR 1306.14(b) requires the central fill pharmacy to affix a label showing the retail pharmacy name and address and a unique identifier (the central fill pharmacy’s DEA registration number) indicating that the prescription was filled at the central fill pharmacy, in addition to the usual CII label elements (fill date, serial number, patient, prescriber, directions). 21 CFR 1306.24(b) is the parallel rule for CIII–V. The exam’s name question is therefore: originating (retail) name and address on the label, central fill identified by DEA number, not a swap that hides the store the patient uses.
Delivery path: the filled CS prescription goes back to the retail pharmacy. Central fill is not mail-order substitution. Keep a record of receipt, method of delivery (private, common, or contract carrier), and the employee who accepted the delivery (21 CFR 1306.15(a)(4)).
Extra DEA paperwork for controlled-substance central fill
21 CFR 1306.15 (CII) and 21 CFR 1306.27 (CIII–V) are matching checklists. The retail pharmacy transmitting the prescription must:
- Write “CENTRAL FILL” on the face of a paper prescription (or add the same data to an electronic record), and record the central fill pharmacy’s name, address, and DEA number, the transmitting pharmacist’s name, and the date of transmittal.
- Transmit all information 21 CFR 1306.05 requires on a prescription.
- Maintain the original prescription (federal two years from fill; Connecticut CS files still three years — more-restrictive Connecticut retention wins).
- Record receipt of the filled prescription (date, carrier method, accepting employee).
The central fill pharmacy must:
- Keep a copy or electronic record of everything transmitted, including the retail pharmacy’s name, address, and DEA number.
- Record date of receipt, the pharmacist who filled it, and the date filled.
- Record the date the filled prescription was delivered to the retail pharmacy and the method of delivery.
Both pharmacies must be DEA-registered. A technician “just faxing it to the warehouse” without a pharmacist transmitting is not 1306.15. Central fill is also not the Chapter 13 transfer of remaining refills to a second retail pharmacy the patient now uses.
503A versus 503B — the table the exam expects
The Drug Quality and Security Act (2013) restored FDCA § 503A and created § 503B outsourcing facilities after the New England Compounding Center meningitis outbreak. Do not treat them as two stickers you can slap on the same hood.
| Feature | 503A traditional pharmacy | 503B outsourcing facility |
|---|---|---|
| Legal home | FDCA § 503A; state pharmacy license (Connecticut § 20-594 or nonresident § 20-627) | FDCA § 503B; FDA registration; still needs whatever state manufacturer/wholesaler or pharmacy credential the destination requires |
| Prescription | Identified individual patient, or limited anticipatory compounding based on a history of orders in an established relationship | With or without a patient-specific prescription; office and hospital stock is the point |
| Quality standard | USP <795>/<797> (and <800> as applicable); exempt from cGMP only if 503A conditions are met | cGMP (not exempt); FDA inspects |
| Copies of commercial products | No compounding regularly or in inordinate amounts of essentially copies of a commercially available drug, unless a documented significant difference for that patient or the product is not commercially available (shortage / off market) | No essentially a copy of an approved drug unless a documented clinical difference or the drug is on FDA’s shortage list |
| Office-use | FDA’s 503A position: not a general office-use statute | Yes — this is how a clinic stocks non-patient-specific CSPs lawfully |
| Mixing at one address | A separate establishment outside the 503B boundary may still do 503A | All drugs compounded at the registered outsourcing facility are regulated under 503B, even if they happen to have patient-specific prescriptions |
FDA’s facility-definition Q&A is the mixing trap: by registering as an outsourcing facility, the entity elects 503B, not 503A. Drugs compounded there are not eligible for 503A exemptions even if each bottle has a patient name. Completely segregated 503A operations, if any, belong in a separate establishment outside that facility’s geographic location or address — not a curtain across the same cleanroom.
Anticipatory 503A compounding is a limited quantity matching historic demand, not a 90-day clinic inventory. Office-use without patient names is a 503B (and, in Connecticut, § 21a-70) problem.
Connecticut overlays — § 21a-70, nonresident § 20-627, sterile § 20-633b
CGS § 20-633b(d)(2) is explicit for sterile product: providing sterile pharmaceuticals without a patient-specific prescription or medical order requires a § 21a-70 certificate of registration and any required federal license or registration. § 21a-70 is Connecticut’s manufacturer and wholesaler drug-registration statute. A 503B that stocks Connecticut clinics is not “just a pharmacy” for that activity.
On-site sterile inventory in that non-patient-specific model is capped at a 30-day supply from completion of compounding, including third-party analytical-testing time (§ 20-633b(d)(2)). That 30-day inventory cap is not RCSA’s older two-week practitioner sentence, and it is not 503A anticipatory compounding.
CGS § 20-627 defines a nonresident pharmacy as any pharmacy located outside this state that ships, mails, or delivers legend drugs or devices into Connecticut pursuant to a prescription order. It must be registered with DCP upon Commission approval. If it sells, delivers, or offers sterile compounded products in Connecticut, it submits the § 20-633b(j) inspection reports (government agency or third-party sterile-compounding expert; P.A. 25-101 as of January 1, 2026). Shipping 503A patient-specific CSPs from New Jersey into Greenwich without that registration is unlicensed nonresident practice. Shipping 503B office-use CSPs into a Hartford clinic without § 21a-70 (and the federal 503B registration) is the other half of the same item.
RCSA’s 30-day nonsterile and two-week sterile practitioner-supply sentences (§§ 20-576-71(c) and 20-576-66(c)) remain on the books. They do not override 503A’s patient-specific limit, 503B/cGMP for true office-use, or § 20-633b(d)(2). More-restrictive law wins.
Realistic Connecticut scenarios
A chain’s New Haven store sends a lisinopril image to the chain’s Wallingford central-fill site. Wallingford fills it and trucks it back. The patient picks up in New Haven and is counseled there. The label shows the New Haven store. That is central fill, not a transfer.
The same patient’s oxycodone goes central fill. New Haven writes CENTRAL FILL with Wallingford’s DEA number; both DEA registrants keep 1306.15 records; the vial shows New Haven’s name and address and Wallingford’s DEA number. Wallingford does not mail oxycodone to the patient’s porch under the central-fill rule.
A Fairfield dermatology office wants 200 unlabeled lidocaine/epinephrine syringes on the shelf with no patient names. A 503A community pharmacy filling that order from its 797 suite is the mixing/office-use trap. The lawful path is a FDA-registered 503B that also holds Connecticut § 21a-70 (and any nonresident credentials if it is out of state), compounding under cGMP.
The same 503B registers at 100 Industrial Way and also wants a “503A corner” of that building for named patients so those bottles can skip cGMP. FDA says no — everything compounded at that registered facility is 503B.
Official anchors
- 21 CFR 1306.14 and 1306.24 — CS labels: retail name/address plus central-fill DEA unique identifier.
- 21 CFR 1306.15 and 1306.27 — CENTRAL FILL documentation for CII and CIII–V.
- FDCA § 503A / § 503B — patient-specific compounding versus FDA-registered cGMP outsourcing; no 503A exemptions inside a 503B facility.
- CGS § 20-633b(d)(2) — § 21a-70 plus federal registration for non-patient-specific sterile pharmaceuticals; 30-day on-site inventory.
- CGS § 20-627 — nonresident pharmacy registration when legend drugs ship into Connecticut.
A Bridgeport retail pharmacy sends a Schedule II oxycodone prescription to a commonly owned Connecticut central-fill pharmacy. Which labeling and counseling statement matches DEA central-fill rules?
A Connecticut clinic wants non-patient-specific sterile injectables on the shelf for office administration. Which legal path matches FDCA § 503B and CGS § 20-633b(d)(2)?
An FDA-registered 503B outsourcing facility in the same building as a Connecticut 503A pharmacy wants patient-specific CSPs from that registered 503B suite to use 503A’s cGMP exemption. What is FDA’s position?